PROGRESS PHARMA
ActiveSummary
PROGRESS PHARMA has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €47,137 and a net result of -€5,479. Equity is shrinking by about 15% per year across the filed financial years. Its solvency ranks better than 90% of 605 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Group and network
Holdings and subsidiaries
1 holding · 4 subsidiaries in the treeHoldings 1
-
100%
All subsidiaries, including indirect ones 4
Companies in which this company or one of its subsidiaries holds more than half, or which it consolidates according to the LEI register.
ETHERNA IMMUNOTHERAPIES 100%3 subsidiaries
- Administratiekantoor eTheRNA Immunotherapies 100%
- eTheRNA Asia LimitedHK 100%
- Etherna Inc.US 100%
According to the 2025 annual accounts of PROGRESS PHARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
5 current directorsThe board mandates are listed below; here you explore them as a network.